Photo taken from Justin Ferdinandus/X
Jul 6, 2024, 09:58
Justin Ferdinandus: BrECADD is better tolerated than eBEACOPP for patients with advanced Hodgkin Lymphoma
Justin Ferdinandus, Resident Physician at University Hospital Cologne, shared on X:
“HD21 results now finally published in The Lancet:
BrECADD is better tolerated and more efficient than eBEACOPP as PET-guided treatment for patients with adv. Hodgkin Lymphoma!”
Source: Justin Ferdinandus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 15:43
Nov 15, 2024, 15:10
Nov 15, 2024, 14:53